43 results about "Persistent pulmonary hypertension" patented technology

An improved pulse oximeter provides for simultaneous, noninvasive oxygen status and photoplethysmograph measurements at both single and multiple sites. In particular, this multiple-site, multiple-parameter pulse oximeter, or “stereo pulse oximeter” simultaneously measures both arterial and venous oxygen saturation at any specific site and generates a corresponding plethysmograph waveform. A corresponding computation of arterial minus venous oxygen saturation is particularly advantageous for oxygen therapy management. An active pulse-inducing mechanism having a scattering-limited drive generates a consistent pulsatile venous signal utilized for the venous blood measurements. The stereo pulse oximeter also measures arterial oxygen saturation and plethysmograph shape parameters across multiple sites. A corresponding calculation of delta arterial saturation and comparison of plethysmograph shape parameters between multiple sites is particularly advantageous for the detection and management of persistent pulmonary hypertension in neonates (PPHN), a patent ductus arteriosis (PDA), and aortic coarctation.

This is directed to methods and devices suited for airway based measurements of pressure in a pulmonary artery. A device is advanced into an airway and in the vicinity of the pulmonary artery. Physical properties of the pulmonary artery are observed through the airway wall using one or more minimally invasive modalities. In a variation, a bronchial balloon catheter measures pressure of the pulmonary artery.

An improved pulse oximeter provides for simultaneous, noninvasive oxygen status and photoplethysmograph measurements at both single and multiple sites. In particular, this multiple-site, multiple-parameter pulse oximeter, or “stereo pulse oximeter” simultaneously measures both arterial and venous oxygen saturation at any specific site and generates a corresponding plethysmograph waveform. A corresponding computation of arterial minus venous oxygen saturation is particularly advantageous for oxygen therapy management. An active pulse-inducing mechanism having a scattering-limited drive generates a consistent pulsatile venous signal utilized for the venous blood measurements. The stereo pulse oximeter also measures arterial oxygen saturation and plethysmograph shape parameters across multiple sites. A corresponding calculation of delta arterial saturation and comparison of plethysmograph shape parameters between multiple sites is particularly advantageous for the detection and management of persistent pulmonary hypertension in neonates (PPHN), a patent ductus arteriosis (PDA), and aortic coarctation.

It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.

The invention relates to a methods and devices of delivering gaseous nitric oxide to a mammal or surface at a concentration ranging from about 1000 ppm to about 50,000 ppm of gaseous nitric oxide. Different conditions which can be treated by high dosage administration of gNO include but are not limited to: topical treatments with gNO, cosmetic applications of gNO, vasodilation conditions with gNO, inhalation treatments with gNO, treatments of the blood with gNO, treatment of the skin or tissue with gNO, treatment of infections with gNO, treatment of inflammation on or within the body, and treatments of biofilms with gNO. Other conditions, aliments, or symptoms that may be treated with high dosage gNO include bronchoconstriction, reversible pulmonary vasoconstriction, asthma, pulmonary hypertension, adult respiratory distress syndrome (ARDS), and persistent pulmonary hypertension of the newborn (PPHN).

A method is disclosed for using fructose-1,6-diphosphate (FDP) to reduce and prevent two very serious problems caused by surgery that requires cardiopulmonary bypass. Before bypass begins, a liquid that contains FDP is intravenously injected into the patient, preferably over a period such as about 10 to 30 minutes, to allow the FDP to permeate in significant quantity into the heart and lungs while the heart is still beating. FDP can be added to the cardioplegia solution that is pumped through the heart to stop the heartbeat, and / or during bypass. This treatment was found to reduce two very important and serious problems that have unavoidably plagued CPB surgery in the past, which are: (1) elevated levels of pulmonary vascular resistance (PVR), which includes pulmonary hypertension; and (2) high occurrence rates for atrial fibrillation. Prior to this discovery, there has never been any satisfactory treatment which could reduce the severity and occurrence rates for these two major problems. FDP also can be co-administered in this manner, along with (1) a buffering or alkalizing agent that counteracts acidosis, such as sodium bicarbonate or THAM, and / or (2) a drug that reduces the formation of lactic acid, such as dichloroacetate.

The present invention is directed to a novel methods and compositions for the therapeutic intervention in persistent pulmonary hypertension of the newborn (PPHN). More specifically, the specification describes methods and compositions for treating various types of PPHN using compositions comprising BH4. Combination therapies of BH4 and other therapeutic regimens are contemplated.

The invention discloses a PTGIS gene mutation related to pulmonary hypertension and application thereof, relating to the field of pulmonary hypertension diseases. According to the invention, through whole genome sequencing, the condition that PTGIS gene has three PTGIS rare variants, namely c.755G more than A, c.1339G more than A and g.23867G more than A positioned at an intron-exon splicing site,which are tightly related to pulmonary hypertension is discovered. For the discovery, one the one hand, the pathogenesis of a patient suffering from pulmonary hypertension is explained favorably, andone the other hand, a mutant type PTGIS gene with the mutation site and corresponding mutation type PTGIS protein are taken as biomarkers of pulmonary hypertension, which can be used for evaluating the risk of the patient suffering from the pulmonary hypertension, or can be used for early warning that the descendant of a PTGIS mutant gene carrier has the risk of suffering from pulmonary hypertension before pregnancy; also the mutation site can be taken as a target point, thus providing a novel concept and measure for treating pulmonary hypertension.

The invention relates to a method for preparing a NO2 adsorption reducing material, which belongs to a method for preparing a gas purifying material and solves the problems of higher micropore proportion, lower mesopore proportion and low NO2 selective adsorption of active carbon prepared by the traditional preparation method. The method sequentially comprises the steps of carbonization, activation and modification processing. The invention can obtain active carbon with high specific surface area, the specific surface areas of a mesopore and a micropore are obviously improved, and the specific surface area of the mesopore is improved to more than 40 percent; and the prepared adsorption reducing material can be used for purifying an inspiratory nitric oxide gas treating relevant diseases, such as acute lung injury and persistent pulmonary hypertension of the new born, high altitude pulmonary edema, lung transplantation reperfusion injury, acute respiratory failure, pulmonary hypertension, and the like, and also be used for separating a NO and NO2 mixed gas to produce a NO gas with high purity.

The invention relates to a new use of a drug, and specifically relates to an effect of atorvastatin on preparation of a drug for treating pulmonary hypertension. The invention discovers for the first time that atorvastatin is capable of alleviating MCT (Monocrotaline)-induced pulmonary inflammation, and inhibiting pulmonary vascular remodeling, pulmonary artery rising and right ventricular hypertrophy without affecting the body circulating pressure; NF-kB is possible to play an important role in the MCT-induced pulmonary hypertension; the atorvastatin is capable of inhibiting the inflammatory reaction by reducing the expression of the MCT-induced pulmonary hypertension lung tissue NF-kB, and is capable of reducing pulmonary vascular remodeling and inhibiting the pulmonary artery high pressure rising; therefore, the atorvastatin can be applied to preparation of the drug for treating the pulmonary hypertension.

Prostaglandin and analogs thereof which include protective groups attached to at least one site which are pharmaceutically acceptable and which are capable of slowing the metabolic rate of the active groups for administration to a warm blooded animal for the treatment of peripheral vascular disease and pulmonary hypertension. In fact, Figure 1 graphically shows the effects on pulmonary arterial pressure of a dose of mPEG20kDa-aminde-Compound X, given as an intravenous infusion to a sheep intravenously-induced with a pulmonary hypertensive agent.

A method of treating pulmonary hypoplasia in infants has been developed, wherein epidermal growth factor (EGF) is administered to the pulmonary system of an infant in need of treatment thereof. The EGF is administered as an aerosol or dry powder directly to the pulmonary tree, or into the amniotic fluid before birth if a situation such as oligohydramnios is recognized pre-term. The method can also be used to treat persistent pulmonary hypertension of the newborn. A hydrophobic angiotensin I-converting enzyme (ACE) inhibitor such as ramipril can also be used for the oral treatment of persistent pulmonary hypertension of the newborn.

The disclosure relates to agents that inhibit the activity of osteoprotegerin and their use in the treatment of pulmonary hypertension.

The invention relates to an establishing method of a PPHN (Persistent Pulmonary Hypertension of Newborn) animal model. The method comprises the following steps of: nurturing a pregnant animal under a hypoxic condition; and treating the pregnant animal by adopting indomethacin twice a day for 3 days, wherein the treatment amount is 0.5 mg / kg, and the oxygen concentration under the hypoxic condition is smaller than 20 percent. Because of applying a hypoxic detection system and injecting the indomethacin in the abdominal cavity, a PPHN rat model of the invention is more accurate and stable to construct and has stronger replicability, and BNP (Brain Natriuretic Peptide) is applied to indirectly measure the pulmonary artery tension of newborn rats so that the model is more reliable to construct. Relative to the construction process of a PPHN model of a large-size animal, the rat PPHN model is easy to establish, has short time period, low cost, convenience, stability and reliability and is suitable for lab researches and applications.

The invention belongs to the field of medicines, and particularly relates to an application of shenxiong glucose injection to preparing a medicine for treating pulmonary hypertension. Clinically, the used amount of shenxiong glucose injection is 200ml for general intravenous injection, once for one day and 14 days for one treatment course. The application is characterized in that the systemic blood pressure (SBP), diastolic blood pressure (DBP), systolic pulmonary artery pressure (sPAP), partial pressure of oxygen (PO2), partial pressure of carbon dioxide (PCO2) and the condition of 6min walking-distance test of a patient with the pulmonary hypertension are monitored, and by contrast observation on all indexes before and after the patient with the pulmonary hypertension accepts the treatment with the shenxiong glucose injection, the shenxiong glucose injection has obvious inhibitory action on the pulmonary hypertension by injection. The shenxiong glucose injection can be used as an ideal medicine for treating the pulmonary hypertension disease.

The invention relates to a preparation method of saponin of radix adenophorae as well as an application of the saponin of radix adenophorae, which is prepared in accordance with technical scheme of the invention, in treating medicines for treating pulmonary arterial hypertension and related cardiovascular diseases caused by the pulmonary arterial hypertension. Based upon experimental studies, the saponin of radix adenophorae provided by the invention can take an obvious effect on reducing mean pulmonary arterial pressure (MPAP), right ventricle systolic pressure (RVSP) and right ventricular hypertrophy index (RVHI) of the pulmonary arterial hypertension. The saponin of radix adenophorae can be used for preventing and treating one or more diseases of special pulmonary arterial hypertension, heritable pulmonary arterial hypertension, drug and poison related pulmonary arterial hypertension, risk factor or disease related pulmonary arterial hypertension, pulmonary arterial hypertension caused by pulmonary veno-occlusive disease and (or) pulmonarycapillary hemangiomatosis, and neonatal persistent pulmonary arterial hypertension.

Method for ameliorating secondary pulmonary hypertension in a patient including determining a pulmonary vascular resistance (PVR) of the patient suffering from secondary pulmonary hypertension; assessing a change in the PVR in response to a selection treatment; and treating the patient with a pulmonary artery manipulation device to provide pulmonary artery denervation if the patient is determined to suffer from fixed PH, thereby ameliorating the secondary pulmonary hypertension of the patient.

The present invention provides devices and system useful for transporting infants, minimizing vibrations, noise, and associated with transport. Devices of the invention include a head gear assembly, one or more body support rolls for elevating portions of the infants body, and a mattress system with a removable insert. The invention further provides methods of use associated with such devices, including methods of stabilizing a position of an infant, reducing shock or vibration to an infant during transportation, reducing shock, vibration, or noise exposure to an infant during transportation, reducing shock or vibration while providing elevation to specific portions of an infant during transportation, and reducing the risk of intraventricular hemorrhage and / or persistent pulmonary hypertension to an infant during transportation.

The invention relates to astragaloside for preventing and treating pulmonary hypertension and a use thereof. The astragaloside (I) is an astragaloside substance extracted from plant radix astragali. The modern pharmacological research result shows that the astragaloside mainly has effects of immune regulation, ischemia protection, cardioprotection, inflammation diminishing, viral resistance and tumor resistance, is used for treating viral myocarditis, cardiac insufficiency and hepatitis caused by dampness stagnancy due to spleen deficiency in clinic, can be used for preventing and / or treatingpulmonary arterial hypertension, can be used for preparation of drugs for reducing pulmonary arterial hypertension-caused rat ventriculus dexter hypertrophy index and mean pulmonary artery pressure, can be used for preparation of drugs for improving plasma NO content and reducing plasma ET-1 content and can be used for preparation of drugs for affecting rat pulmonary arterial hypertension tissue pathological structures.

Methods and compositions for treating lung conditions such as bronchopulmonary dysplasia or hypoxia-induced pulmonary hypertension in a subject, including administering to the subject an effective amount of a nitric oxide precursor such as citrulline.

The invention relates to a preparation method and novel applications of lobelia intiata extract. According to the technical scheme provided by the invention, the lobelia intiata extract is used for treating pulmonary hypertension, and cardiovascular relevant diseases caused by pulmonary hypertension. The experimental study shows that the lobelia intiata extract provided by the invention can be used for preparing medicines for preventing or treating pulmonary hypertension, wherein the pulmonary hypertension comprises one or more symptoms of pulmonary arterial hypertension, pulmonary hypertension relevant to chronic hypoxic diseases, chronic thromboembolism pulmonary hypertension, and pulmonary hypertension caused by various unknown factors.

The invention discloses application of Tongxinluo in preparing a medicament for treating pulmonary hypertension, relating to the field of pharmaceutical chemistry. Proven by experiments, the Tongxinluo can reduce the mean pulmonary artery pressure of a white rat with pulmonary hypertension, improve the cardiac output, reduce the pulmonary vascular resistance, and improve right ventricle remodeling and pulmonary vascular remodeling. Long-term usage of the Tongxinluo can effectively treat pulmonary hypertension and improve the right heart function.

The invention discloses application of formononetin to preparation of drugs for treating pulmonary hypertension and the drugs for treating pulmonary hypertension. The pulmonary hypertension drugs areoral drugs or injection drugs. The pulmonary hypertension drugs in the form of injection drugs are obtained by dissolving the formononetin in pharmaceutical solvents. The pharmaceutical solvents comprise dimethyl sulfoxide and / or olive oil. According to the present invention, the proliferation of pulmonary artery smooth muscle cells can be inhibited and the apoptosis of the pulmonary artery smoothmuscle cells can be promoted by the formononetin, pulmonary vascular remodeling can be significantly improved, pulmonary vascular resistance and pulmonary artery pressure can be reduced, the formononetin plays a role in reducing blood pressure stably, pulmonary function and right heart function can be restored, human impaired function can be normalized and complications can be treated as a whole.

The disclosure relates to agents that inhibit the activity of osteoprotegerin and their use in the treatment of pulmonary hypertension.

The invention relates to the field of medical treatment and health care, in particular to the application of melatonin and / or inflammatory body inhibitors in the preparation of drugs for treating pulmonary hypertension. The invention utilizes hypoxia to induce mice to produce pulmonary artery hypertension, mice are then treated with melatonin and inflammatory body inhibitor alone or in combination, the right ventricular hypertrophy index, right ventricular systolic blood pressure and pulmonary pathology are observed, and the effect of melatonin on the pathological development of pulmonary hypertension is confirmed by statistics of vascular remodeling rate, and the effect of melatonin on inflammatory bodies is verified by in vitro cells. The results show that melatonin and inflammatory bodyinhibitor have good therapeutic effect on pulmonary hypertension, and could significantly reduce right ventricular systolic blood pressure, inhibit the activation of inflammatory body, and achieve the purpose of treating pulmonary hypertension. At the same time, the combination of melatonin and inflammatory body inhibitor has more significant effect.

The invention discloses application of Tongxinluo in preparing a medicament for treating pulmonary hypertension, relating to the field of pharmaceutical chemistry. Proven by experiments, the Tongxinluo can reduce the mean pulmonary artery pressure of a white rat with pulmonary hypertension, improve the cardiac output, reduce the pulmonary vascular resistance, and improve right ventricle remodeling and pulmonary vascular remodeling. Long-term usage of the Tongxinluo can effectively treat pulmonary hypertension and improve the right heart function.

The invention discovers novel application of glucagon-like peptde-1 receptor agonist to preparation of a pulmonary hypertension treating medicine for the first time. It is proved through various experiments that the medicine can effectively reduce the cell glycolysis level, restrain the abnormal proliferation of pulmonary vascular cells and remarkably relieve pulmonary vascular reconstruction, thereby reducing pulmonary vascular resistance and pulmonary artery pressure and treating pulmonary hypertension.

The invention relates to a method for preparing a NO2 adsorption reducing material, which belongs to a method for preparing a gas purifying material and solves the problems of higher micropore proportion, lower mesopore proportion and low NO2 selective adsorption of active carbon prepared by the traditional preparation method. The method sequentially comprises the steps of carbonization, activation and modification processing. The invention can obtain active carbon with high specific surface area, the specific surface areas of a mesopore and a micropore are obviously improved, and the specific surface area of the mesopore is improved to more than 40 percent; and the prepared adsorption reducing material can be used for purifying an inspiratory nitric oxide gas treating relevant diseases, such as acute lung injury and persistent pulmonary hypertension of the new born, high altitude pulmonary edema, lung transplantation reperfusion injury, acute respiratory failure, pulmonary hypertension, and the like, and also be used for separating a NO and NO2 mixed gas to produce a NO gas with high purity.

A method and device for discharging an electrical defibrillation pulse or an electrical demand pacer pulse or delivering at least one pharmaceutical agent to treat conditions such as cardiac arrest, bradycardia, arrhythmia, cardiac standstill, PEA, EMD and other heart conditions are disclosed. The pharmaceutical agent can be delivered into the heart tissue, the heart cavity, or the peritoneal cavity. The pharmaceutical agent can also include analgesics such as morphine. Also included are pharmaceutical agents used to increase myocardial contractility or inhibit platelet aggregation and vasoactive intestinal polypeptide (VIP) and thyroid hormones such as T3 and T4 can be delivered. A method for the treatment of cardiac arrest or pulmonary hypertension patients by administering a therapeutically effective amount of vasoactive intestinal polypeptide is also encompassed by the invention.

A primary object of the present invention is to provide a method for conveniently and accurately testing for pulmonary hypertension. To achieve this object, the present invention provides a method for testing for pulmonary hypertension using as an indicator the concentration of selenoprotein P protein in a sample derived from a subject.